We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ATNXQ Athenex Inc (CE)

0.00 (0.00%)
Apr 11 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0.00
Bid Price
Ask Price
News -
Day High


52 Week Range


Day Low
Share Name Share Symbol Market Stock Type
Athenex Inc (CE) ATNXQ OTCMarkets Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.0152 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.0152 0.0152
Trades Shares Traded Average Volume 52 Week Range
0 0.00 - 0.0003 - 0.23
Last Trade Type Quantity Price Currency
- 0 US$ 0.0152 USD

Athenex Inc (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 131.68k 8.66M - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Athenex (CE) News

Date Time Source News Article
10/02/202306:42Edgar (US Regulatory)Form 8-K - Current report
8/17/202315:06Edgar (US Regulatory)Form 8-K - Current report
7/18/202308:03Edgar (US Regulatory)Form 8-K - Current report
7/10/202305:05Edgar (US Regulatory)Form 25-NSE - Notification filed by national security..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ATNXQ Message Board. Create One! See More Posts on ATNXQ Message Board See More Message Board Posts

Historical ATNXQ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.1380.230.00030.138748250,650-0.1228-88.99%
3 Years0.1380.230.00030.138748250,650-0.1228-88.99%
5 Years0.1380.230.00030.138748250,650-0.1228-88.99%

Athenex (CE) Description

Athenex is a clinical stage biotechnology company focused on the development of autologous and allogeneic NKT cell therapies to treat cancers. The company's goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes of cancer patients.

Your Recent History

Delayed Upgrade Clock